Biomimetic cell-derived nanocarriers in cancer research
Abstract Nanoparticles have now long demonstrated capabilities that make them attractive to use in biology and medicine. Some of them, such as lipid nanoparticles (SARS-CoV-2 vaccines) or metallic nanoparticles (contrast agents) are already approved for their use in the clinic. However, considering...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-12-01
|
| Series: | Journal of Nanobiotechnology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12951-022-01748-4 |
| _version_ | 1797977297780736000 |
|---|---|
| author | Enrica Soprano Ester Polo Beatriz Pelaz Pablo del Pino |
| author_facet | Enrica Soprano Ester Polo Beatriz Pelaz Pablo del Pino |
| author_sort | Enrica Soprano |
| collection | DOAJ |
| description | Abstract Nanoparticles have now long demonstrated capabilities that make them attractive to use in biology and medicine. Some of them, such as lipid nanoparticles (SARS-CoV-2 vaccines) or metallic nanoparticles (contrast agents) are already approved for their use in the clinic. However, considering the constantly growing body of different formulations and the huge research around nanomaterials the number of candidates reaching clinical trials or being commercialized is minimal. The reasons behind being related to the “synthetic” and “foreign” character of their surface. Typically, nanomaterials aiming to develop a function or deliver a cargo locally, fail by showing strong off-target accumulation and generation of adverse responses, which is connected to their strong recognition by immune phagocytes primarily. Therefore, rendering in negligible numbers of nanoparticles developing their intended function. While a wide range of coatings has been applied to avoid certain interactions with the surrounding milieu, the issues remained. Taking advantage of the natural cell membranes, in an approach that resembles a cell transfer, the use of cell-derived surfaces has risen as an alternative to artificial coatings or encapsulation methods. Biomimetic technologies are based on the use of isolated natural components to provide autologous properties to the nanoparticle or cargo being encapsulated, thus, improving their therapeutic behavior. The main goal is to replicate the (bio)-physical properties and functionalities of the source cell and tissue, not only providing a stealthy character to the core but also taking advantage of homotypic properties, that could prove relevant for targeted strategies. Such biomimetic formulations have the potential to overcome the main issues of approaches to provide specific features and identities synthetically. In this review, we provide insight into the challenges of nano-biointerfaces for drug delivery; and the main applications of biomimetic materials derived from specific cell types, focusing on the unique strengths of the fabrication of novel nanotherapeutics in cancer therapy. Graphical Abstract |
| first_indexed | 2024-04-11T05:04:39Z |
| format | Article |
| id | doaj.art-d571000ffe6d46c68e1b43ece05e9ad0 |
| institution | Directory Open Access Journal |
| issn | 1477-3155 |
| language | English |
| last_indexed | 2024-04-11T05:04:39Z |
| publishDate | 2022-12-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Nanobiotechnology |
| spelling | doaj.art-d571000ffe6d46c68e1b43ece05e9ad02022-12-25T12:28:03ZengBMCJournal of Nanobiotechnology1477-31552022-12-0120111610.1186/s12951-022-01748-4Biomimetic cell-derived nanocarriers in cancer researchEnrica Soprano0Ester Polo1Beatriz Pelaz2Pablo del Pino3Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CiQUS), Universidade de Santiago de CompostelaCentro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CiQUS), Universidade de Santiago de CompostelaCentro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CiQUS), Universidade de Santiago de CompostelaCentro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CiQUS), Universidade de Santiago de CompostelaAbstract Nanoparticles have now long demonstrated capabilities that make them attractive to use in biology and medicine. Some of them, such as lipid nanoparticles (SARS-CoV-2 vaccines) or metallic nanoparticles (contrast agents) are already approved for their use in the clinic. However, considering the constantly growing body of different formulations and the huge research around nanomaterials the number of candidates reaching clinical trials or being commercialized is minimal. The reasons behind being related to the “synthetic” and “foreign” character of their surface. Typically, nanomaterials aiming to develop a function or deliver a cargo locally, fail by showing strong off-target accumulation and generation of adverse responses, which is connected to their strong recognition by immune phagocytes primarily. Therefore, rendering in negligible numbers of nanoparticles developing their intended function. While a wide range of coatings has been applied to avoid certain interactions with the surrounding milieu, the issues remained. Taking advantage of the natural cell membranes, in an approach that resembles a cell transfer, the use of cell-derived surfaces has risen as an alternative to artificial coatings or encapsulation methods. Biomimetic technologies are based on the use of isolated natural components to provide autologous properties to the nanoparticle or cargo being encapsulated, thus, improving their therapeutic behavior. The main goal is to replicate the (bio)-physical properties and functionalities of the source cell and tissue, not only providing a stealthy character to the core but also taking advantage of homotypic properties, that could prove relevant for targeted strategies. Such biomimetic formulations have the potential to overcome the main issues of approaches to provide specific features and identities synthetically. In this review, we provide insight into the challenges of nano-biointerfaces for drug delivery; and the main applications of biomimetic materials derived from specific cell types, focusing on the unique strengths of the fabrication of novel nanotherapeutics in cancer therapy. Graphical Abstracthttps://doi.org/10.1186/s12951-022-01748-4Biomimetic nanocarrierDrug deliveryIntracellular deliveryCancer therapyCell-membrane coating Nanoparticles |
| spellingShingle | Enrica Soprano Ester Polo Beatriz Pelaz Pablo del Pino Biomimetic cell-derived nanocarriers in cancer research Journal of Nanobiotechnology Biomimetic nanocarrier Drug delivery Intracellular delivery Cancer therapy Cell-membrane coating Nanoparticles |
| title | Biomimetic cell-derived nanocarriers in cancer research |
| title_full | Biomimetic cell-derived nanocarriers in cancer research |
| title_fullStr | Biomimetic cell-derived nanocarriers in cancer research |
| title_full_unstemmed | Biomimetic cell-derived nanocarriers in cancer research |
| title_short | Biomimetic cell-derived nanocarriers in cancer research |
| title_sort | biomimetic cell derived nanocarriers in cancer research |
| topic | Biomimetic nanocarrier Drug delivery Intracellular delivery Cancer therapy Cell-membrane coating Nanoparticles |
| url | https://doi.org/10.1186/s12951-022-01748-4 |
| work_keys_str_mv | AT enricasoprano biomimeticcellderivednanocarriersincancerresearch AT esterpolo biomimeticcellderivednanocarriersincancerresearch AT beatrizpelaz biomimeticcellderivednanocarriersincancerresearch AT pablodelpino biomimeticcellderivednanocarriersincancerresearch |